Paper14769732
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
Moss RB and 11 others. Chest, 2004. Cited by 294 papers, by iCite.
Cite this record
ConductScience Library. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Papers, record 14769732. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/14769732
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
- PubMed
- Publication types
- Clinical Trial, Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cystic Fibrosis | Major topic |
| Cystic Fibrosis Transmembrane Conductance Regulator | Major topic |
| Genetic Therapy | Major topic |
| Administration, Inhalation | |
| Adolescent | |
| Adult | |
| Aerosols | |
| Analysis of Variance | |
| Bronchoscopy | |
| Child | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Drug Administration Schedule | |
| Female | |
| Gene Transfer Techniques | |
| Humans | |
| Male | |
| Probability | |
| Respiratory Function Tests | |
| Risk Assessment | |
| Severity of Illness Index | |
| Statistics, Nonparametric | |
| Treatment Outcome |
Source PubMed
Cited by139
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 294 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42654157 | Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42654157 | PubMed |
| 42376650 | CFTR gene delivery to human airway epithelia using parainfluenza virus 5 amplifying virus-like particles. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42376650 | PubMed |
| 42278347 | Safety of Adeno-Associated Viral Vectors in Gene Therapy: Mechanisms of Toxicity, Clinical Risks, and Strategies for Their Minimization. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278347 | PubMed |
| 42182483 | Optimized AAV capsids robustly transduce airway epithelial cells. | bioRxiv | 2026 | https://conductscience.org/library/papers/42182483 | PubMed |
| 41977378 | Immune Toxicities in AAV Gene Therapy: Overview for Clinicians. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977378 | PubMed |
| 41866915 | Inhalable gene and RNA therapy for cystic fibrosis: perspectives and progress in clinical development. | Nanomedicine (Lond) | 2026 | https://conductscience.org/library/papers/41866915 | PubMed |
| 41789512 | Autocrine SFRP2 (secreted frizzled related protein 2) enhances lung myofibroblast fibrogenic activity by suppressing PINK1-mediated mitophagy initiation. | Autophagy | 2026 | https://conductscience.org/library/papers/41789512 | PubMed |
| 41613863 | Genetically engineered approaches to the treatment of cystic fibrosis. | Biophys Rev | 2025 | https://conductscience.org/library/papers/41613863 | PubMed |
| 40752498 | Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials. | Lancet Respir Med | 2025 | https://conductscience.org/library/papers/40752498 | PubMed |
| 40665138 | Advances and Challenges in Adeno-Associated Virus Gene Therapy Applications of Localized Delivery Strategies. | Curr Med Sci | 2025 | https://conductscience.org/library/papers/40665138 | PubMed |
| 40430940 | Generation and Treatment of a Novel Severe Model of Visceral Gaucher Disease by Genetic Therapy. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40430940 | PubMed |
| 40380180 | Inhibition of DLK1 regulates AT2 differentiation and alleviates established pulmonary fibrosis by upregulating TTF-1/CLDN6. | Respir Res | 2025 | https://conductscience.org/library/papers/40380180 | PubMed |
| 40006994 | Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy. | Viruses | 2025 | https://conductscience.org/library/papers/40006994 | PubMed |
| 39583120 | Mechanism of Genome Editing Tools and Their Application on Genetic Inheritance Disorders. | Glob Med Genet | 2024 | https://conductscience.org/library/papers/39583120 | PubMed |
| 39225214 | Recent Advances in Therapeutics and Manufacturing Processes of Recombinant Adeno-Associated Virus for the Treatment of Lung Diseases. | Curr Gene Ther | 2025 | https://conductscience.org/library/papers/39225214 | PubMed |
| 39199292 | Aerosol Inhalation of Gene Delivery Therapy for Pulmonary Diseases. | Biomolecules | 2024 | https://conductscience.org/library/papers/39199292 | PubMed |
| 39069560 | Amelioration of airway and GI disease in G551D-CF ferrets by AAV1 and AAV6. | Gene Ther | 2024 | https://conductscience.org/library/papers/39069560 | PubMed |
| 38323309 | Understanding AAV vector immunogenicity: from particle to patient. | Theranostics | 2024 | https://conductscience.org/library/papers/38323309 | PubMed |
| 38247731 | Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care. | BioTech (Basel) | 2024 | https://conductscience.org/library/papers/38247731 | PubMed |
| 38077224 | Reciprocal mutations of lung-tropic AAV capsids lead to improved transduction properties. | Front Genome Ed | 2023 | https://conductscience.org/library/papers/38077224 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CFTR | 1080 | PubTator's text mining | https://conductscience.org/library/genes/1080 | NCBI Gene |
| CXCL8 | 3576 | PubTator's text mining | https://conductscience.org/library/genes/3576 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/14769732
GET https://conductscience.org/api/papers/v1/14769732/cited_by?page=2